Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · third_quarter · Q3
General issues related to Buy American/American First; and issues related to North American Free Trade Agreement.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Source: Senate LDA
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Restoring Access to Medication Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
Lower Drug Costs through Competition Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Lower Drug Costs through Competition Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Protecting Seniors Access to Medicare Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Protecting Seniors' Access to Medicare Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Protecting Seniors' Access to Medicare Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to S.637 "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017.
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Restoring Access to Medication Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Strengthening Public Health Emergency Response Act of 2016
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Strengthening Public Health Emergency Response Act of 2016
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks; issues related to Center for Medicaid and Medicaid Services Innovation Center; Issues related to research and development innovation and education; general issues related to insulin pricing; general issues related to Tropical Disease PRV Program; general issues related to Vaccine Safety; issues related to Access to Adult Vaccines; issues related to H.R. 3299 Strengthening Public Health Emergency Response Act; importation issues related to S.122 Safe and Affordable Drugs from Canada Act of 2015; issues related to pricing and cost value; issues related to the Prescription Drug User Fee Act; and issues related to 21st Century Cures Initiative.
Preserving Access to Orphan Drugs Act of 2015
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Adding Zika Virus to the FDA Priority Review Voucher Program Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Zika Response Appropriations Act, 2016
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Zika Response Appropriations Act, 2016
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Safe and Affordable Drugs from Canada Act of 2015
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks; issues related to Center for Medicaid and Medicaid Services Innovation Center; Issues related to research and development innovation and education; general issues related to insulin pricing; general issues related to Tropical Disease PRV Program; general issues related to Vaccine Safety; issues related to Access to Adult Vaccines; issues related to H.R. 3299 Strengthening Public Health Emergency Response Act; importation issues related to S.122 Safe and Affordable Drugs from Canada Act of 2015; issues related to pricing and cost value; issues related to the Prescription Drug User Fee Act; and issues related to 21st Century Cures Initiative.
Adding Zika Virus to the FDA Priority Review Voucher Program Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Medicare Prescription Drug Price Negotiation Act of 2015
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to the Medicare Part D Program and government price setting; and provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement and Center for Medicaid and Medicare Innovation Part B rule
Medicare Prescription Drug Price Negotiation Act of 2015
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Provisions of S.31 "Medicare Prescription Drug Price Negotiation Act; issues related to Medicare Part B reimbursement; and issues related to Medicare Part D program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · second_quarter · Q2
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
General issues related to Buy American/American First; issues related to international drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · first_quarter · Q1
General issues related to S.637 "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017.
General issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
General issues related to Buy American/American First; issues related to international drug pricing and reimbursement; and issues related to international market access.
General issues related to patent reform.
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · fourth_quarter · Q4
Provisions of S.31 "Medicare Prescription Drug Price Negotiation Act; issues related to Medicare Part B reimbursement; and issues related to Medicare Part D program
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks; issues related to Center for Medicaid and Medicaid Services Innovation Center; Issues related to research and development innovation and education; general issues related to insulin pricing; general issues related to Tropical Disease PRV Program; general issues related to Vaccine Safety; issues related to Access to Adult Vaccines; issues related to H.R. 3299 Strengthening Public Health Emergency Response Act; importation issues related to S.122 Safe and Affordable Drugs from Canada Act of 2015; issues related to pricing and cost value; issues related to the Prescription Drug User Fee Act; and issues related to 21st Century Cures Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · third_quarter · Q3
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · second_quarter · Q2
General issues related to the Medicare Part D Program and government price setting; and provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement and Center for Medicaid and Medicare Innovation Part B rule
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)